Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Common Equity (2022 - 2025)

Historic Common Equity for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $728.1 million.

  • NewAmsterdam Pharma's Common Equity rose 9217.29% to $728.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $728.1 million, marking a year-over-year increase of 9217.29%. This contributed to the annual value of $757.5 million for FY2024, which is 16266.24% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's Common Equity stood at $728.1 million, which was up 9217.29% from $778.5 million recorded in Q2 2025.
  • In the past 5 years, NewAmsterdam Pharma's Common Equity ranged from a high of $778.5 million in Q2 2025 and a low of $288.4 million during Q4 2023
  • Moreover, its 4-year median value for Common Equity was $405.1 million (2023), whereas its average is $508.8 million.
  • In the last 5 years, NewAmsterdam Pharma's Common Equity plummeted by 4166.0% in 2023 and then surged by 16266.24% in 2024.
  • NewAmsterdam Pharma's Common Equity (Quarter) stood at $494.3 million in 2022, then crashed by 41.66% to $288.4 million in 2023, then soared by 162.66% to $757.5 million in 2024, then fell by 3.89% to $728.1 million in 2025.
  • Its last three reported values are $728.1 million in Q3 2025, $778.5 million for Q2 2025, and $777.4 million during Q1 2025.